Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo Nordisk stock currently costs less than 14 times earnings.

With Novo Nordisk shedding double digits following its latest guidance cut, is this a chance to buy the dip or a warning sign of deeper trouble ahead?

The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans [using copycat versions](